Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Shares Move to Nasdaq National Market

NEW YORK, Dec. 19 (GenomeWeb News) - Nasdaq moved Clinical Data's exchange listing from the Capital Market to the National Market, Clinical Data said today.

 

Clinical Data's shares began trading on the Nasdaq National Market this morning. The company's stock symbol, CLDA, remains the same.

 

The Nasdaq Capital Market was formerly known as the Nasdaq Small Cap Market.

 

According to Israel Stein, Clinical Data's president and CEO, the move will "build shareholder value" as the company continues to integrate Genaissance Pharmaceuticals and Icoria.

 

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.